Companies › Outpace Bio
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OPB-201 autologous TCR T cell therapy targeting PRAME peptide with optimized alpha and beta chains | – | Phase 1 | Endometrial Cancer Recurrent | Jun 2030 |
| OPB-101 Autologous mesothelin (MSLN) CAR T cell therapy with antigen-dependent expression of OUTSM | – | Phase 1 | Ovarian Cancer Recurrent | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07030907 | OPB-101 | Phase 1 | Ovarian Cancer Recurrent | Oncology | Sep 2026 |
| NCT07664735 | OPB-201 | Phase 1 | Endometrial Cancer Recurrent | Oncology | Jun 2030 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.